8-K: Neumora Converts $2.5M Debt to Equity with K2HV

Neumora Therapeutics, Inc. issued 2.85 million common shares to K2 HealthVentures Equity Trust LLC by converting $2.5 million of a term loan at $0.8774 per share.

Summary

• Neumora Therapeutics, Inc. completed an unregistered sale of equity securities by converting a portion of its term loan.
• K2 HealthVentures LLC (K2HV) elected to convert $2.5 million of the outstanding principal of its term loan into common stock.
• The conversion price was set at $0.8774 per share.
• On November 20, 2025, 2,849,327 shares of common stock were issued to K2 HealthVentures Equity Trust LLC.
• The shares were issued under the registration exemption provided by Section 4(a)(2) of the Securities Act of 1933.
• K2HV retains the right to convert up to an aggregate of $12.5 million of the term loans, meaning an additional $10 million could still be converted.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the immediate dilution for existing shareholders, despite the positive aspect of debt reduction. The conversion price also warrants scrutiny.

Positives

• The conversion reduces the company's outstanding debt by $2.5 million, strengthening the balance sheet.
• This transaction demonstrates K2HV's continued investment and potential long-term commitment to the company, shifting from a pure debt holder to an equity stakeholder.

Negatives

• The issuance of 2,849,327 new common shares results in dilution for existing shareholders.
• The conversion price of $0.8774 per share may be below the current market price, potentially indicating a discount or a valuation from a prior agreement.

Risks

• Further dilution of existing shareholders is possible as K2HV retains the right to convert up to an additional $10 million of the term loan principal.
• The conversion price could set a benchmark or perception of valuation for future equity transactions.

Future Outlook

K2 HealthVentures LLC retains the right to convert up to an additional $10 million of the outstanding principal of the term loans into common stock, which could lead to further equity dilution.

Industry Context

Debt-to-equity conversions are a common financing mechanism in the biotechnology sector, particularly for development-stage companies like Neumora, to manage debt obligations and extend cash runways. K2 HealthVentures is a specialized healthcare investment firm, indicating a strategic financial partnership.

Comparison to Industry Standards

• NA This is a specific debt-to-equity conversion event rather than a performance metric that can be directly compared to industry benchmarks or specific competitor results without additional context on the company's overall financial health and market conditions at the time of conversion.

Related Party Transactions

• K2 HealthVentures LLC, as a lender under the Loan and Security Agreement, converted a portion of its term loan into equity, representing a transaction with a significant financial partner.

Stakeholder Impact

• Shareholders: Experience dilution of their ownership percentage due to the issuance of new common shares.
• Creditors (K2HV): Their debt exposure is reduced by $2.5 million, and they gain an increased equity stake in the company.

Next Steps

• Potential future conversions by K2 HealthVentures LLC of up to an additional $10 million of term loan principal into common stock.

Key Dates

Recommendation

The debt-to-equity conversion reduces the company's outstanding debt, which is a positive for the balance sheet. However, the issuance of 2,849,327 new shares at $0.8774 per share results in dilution for existing shareholders. Without further financial performance data or market context, a 'hold' recommendation is appropriate as the positive of debt reduction is balanced by the negative of dilution.

Keywords

Neumora Therapeutics, NMRA, Debt Conversion, Equity Issuance, K2 HealthVentures, 8-K Filing, Common Stock, Dilution, Biotechnology, Term Loan